Immunohistochemistry Market Regional Analysis

Immunohistochemistry Market size was valued at USD 3.1 Billion in 2023 and is poised to grow from USD 3.33 Billion in 2024 to USD 5.91 Billion by 2032, growing at a CAGR of 7.4% during the forecast period (2025-2032).

Investing in the development of immunohistochemistry-based diagnostics will be the most rewarding opportunity for any market player. Creating affordable immunohistochemistry solutions that can be used by establishments with limited budgets will help immunohistochemistry companies expand their business in developing countries going forward. New product launches and collaborations are slated to be popular strategies for all immunohistochemistry companies. 'F. Hoffmann-La Roche Ltd. ', 'Danaher Corporation ', 'Agilent Technologies Inc. ', 'PHC Holdings Corporation ', 'Thermo Fisher Scientific Inc. ', 'Merck KGaA ', 'Bio-Rad Laboratories, Inc. ', 'Bio-Techne ', 'Becton, Dickinson and Company ', 'Takara Bio Inc. ', 'Enzo Biochem Inc. ', 'Sino Biological, Inc. ', 'Sakura Finetek Japan Co., Ltd. ', 'Cell Signaling Technology, Inc. ', 'BIO SB ', 'Miltenyi Biotec ', 'OriGene Technologies, Inc. ', 'EagleBio ', 'Biocare Medical, LLC ', 'Elabscience Bionovation Inc. ', 'BioGenex ', 'Diagnostic BioSystems Inc. ', 'Histo-Line Laboratories ', 'Rockland Immunochemicals, Inc. ', 'Candor Bioscience GmbH ', 'Genemed Biotechnologies, Inc.'

Immunohistochemistry plays a vital role in the diagnostics of multiple chronic diseases, and this is why as the prevalence of chronic diseases increases around the world it is also expected to influentially drive up the demand for immunohistochemistry products and technologies as well.  

Automation is projected to be a major trend across all industry verticals in the future. Development of automated immunohistochemistry solutions will also offer highly lucrative opportunities for all immunohistochemistry market players in the future. Use of artificial intelligence will play a vital role in promoting automation.

North America is projected to account for a dominant the global immunohistochemistry market share. The presence of a strong medical research infrastructure, supportive government funding for research, and rising demand for early diagnostics are forecasted to create new opportunities for immunohistochemistry market players. The United States is projected to lead the demand for immunohistochemistry in this region owing to the presence of multiple pharmaceutical and biotechnology companies in the country. Canada is also expected to provide lucrative opportunities for immunohistochemistry companies as demand for better diagnostic products increases.